Pacira BioSciences Earnings Call Transcripts
Fiscal Year 2026
-
Management outlined a robust growth strategy centered on expanding non-opioid pain management, leveraging strong Q1 results, and advancing a diversified pipeline. Key catalysts include upcoming data readouts, expanded market access, and a strengthened patent estate supporting long-term exclusivity.
-
The company is executing a 5x30 growth strategy, expanding payer access and partnerships, and expects double-digit growth for EXPAREL. Key pipeline readouts, including PCRX-201 for knee OA, are anticipated by year-end, while robust IP and manufacturing complexity protect market position.
-
Q1 2026 showed strong volume and revenue growth, with the gap expected to narrow as GPO discounting eases. Expansion of coverage and adoption of the NOPAIN Act are key growth drivers, supported by robust clinical evidence and a pipeline rich in late-stage data. International partnerships and disciplined capital allocation underpin long-term growth ambitions.
-
Q1 2026 delivered strong revenue and volume growth across all major products, supported by expanding reimbursement, strategic partnerships, and robust pipeline progress. Guidance for 2026 was reiterated, with disciplined capital allocation and continued share repurchases.
-
The conference highlighted strong 2025 financials, robust growth in EXPAREL, and the strategic 5x30 plan targeting five pillars by 2030. Key pipeline milestones, expanded partnerships, and improved reimbursement are expected to drive future growth and market leadership.
-
The conference highlighted strong execution on the 5x30 strategy, with robust volume growth for EXPAREL, expanded reimbursement through NOPAIN, and key partnerships with J&J and LG Chem. Pipeline progress, especially with PCRX-201, and a solid financial outlook position the company for continued double-digit growth.
-
The company reported strong growth, expanded its IP estate, and advanced its 5x30 strategy, including new partnerships and pipeline progress. NOPAIN legislation and increased market access are driving steady volume growth, while upcoming data readouts for key products are expected to further support momentum.
Fiscal Year 2025
-
2025 saw record revenue and gross margins, driven by EXPAREL growth, expanded payer coverage, and strategic partnerships. 2026 guidance projects continued steady growth, with new pipeline milestones and ex-U.S. revenues expected in 2027.
-
Three marketed non-opioid pain products drive strong revenue, with a robust pipeline including PCRX-201 gene therapy. Strategic goals target patient growth, margin improvement, and global expansion, while regulatory changes and focused sales strategies support future growth.
-
The company targets double-digit growth and margin expansion by 2030, driven by Exparel’s accelerating adoption, new reimbursement catalysts, and operational efficiencies. Pipeline progress, especially with PCRX-201, and strategic partnerships are expected to further boost growth.
-
Q3 2025 saw 6% revenue growth, led by EXPAREL's 9% volume increase and strong iovera sales. Gross margin improved to 82%, and full-year guidance was raised. Strategic investments, new product in-licensing, and expanded market access position the business for continued growth.
-
Second quarter results showed strong execution, with EXPAREL sales up 6% year-over-year and gross margins improving to 82%. Revenue guidance was narrowed to $730M-$750M, and a new J&J MedTech partnership is set to accelerate ZILRETTA growth.
-
The company is leveraging its market-leading non-opioid pain therapies and a unique settlement for Exparel to ensure long-term exclusivity and cash flow. Early benefits from the No Pain Act and commercial payer adoption are driving growth, while the '5 by 30' plan targets margin expansion, pipeline innovation, and strategic partnerships.
-
The company is leveraging strong cash flow from its pain management portfolio to drive innovation, with a clear 5x30 strategy targeting growth, margin expansion, and pipeline development. Recent litigation settlements provide long-term visibility, while PCRX 201 and a new gene therapy platform highlight future potential.
-
Q1 saw strong Exparel growth, improved gross margins, and a $300M share repurchase authorization. Patent litigation settlement extends Exparel exclusivity to 2039, supporting long-term growth and cash flow. Guidance for 2025 is reiterated, with No Pain adoption expected to accelerate in H2.
-
PCRX-201, an investigational gene therapy for knee osteoarthritis, showed significant and durable pain relief in a phase I trial, leading to FDA RMAT designation. Phase II is underway, focusing on safety and efficacy, with interim data expected by late 2026.
-
The conference highlighted a five-year strategic plan to drive growth through commercial expansion, new partnerships, and pipeline innovation. Key products are positioned for growth via regulatory incentives and expanded reimbursement, while ongoing IP litigation and R&D efforts support long-term value.
-
Strong financial performance and commercial progress were highlighted, with major R&D advances including the GQ Bio acquisition and pipeline expansion. Legal strategies are in place to defend key patents, while operational focus remains on margin improvement and capital allocation.
-
Management outlined a 5x30 strategy targeting double-digit growth, margin expansion, and pipeline innovation, leveraging the No Pain Act and expanded GPO partnerships. Key pipeline assets, including PCRX-201, are advancing, with major readouts expected by 2026.
-
Strong 2024 execution set the stage for a 5x30 growth plan, targeting over 3 million patients by 2030 and double-digit CAGR. Key products benefit from new reimbursement and pipeline advances, while legal and IP positions remain robust.
Fiscal Year 2024
-
Record 2024 revenues and strong commercial execution position the company for double-digit growth, with expanded reimbursement, new product launches, and a robust pipeline. 2025 guidance anticipates continued volume-driven revenue gains and margin expansion, supported by targeted investments and strategic acquisitions.
-
Expanded IP protection for EXPAREL and a multi-layered litigation strategy aim to delay generic entry until at least 2026. NOPAIN legislation and new reimbursement codes are expected to drive significant volume growth, with manufacturing capacity ramping up and a promising pipeline supporting long-term value creation.
-
Management highlighted consistent performance, strategic focus on musculoskeletal pain, and major GPO contracts covering 80% of business by 2025. NOPAIN reimbursement launches in January, expanding the addressable market, with gradual adoption expected. Legal proceedings continue, but no generic launch is imminent, and the pipeline shows promise with new therapies and studies underway.
-
Third-quarter results showed strong sales and margin performance, with Exparel and iovera gaining expanded reimbursement and new codes under NOPAIN. The company reiterated 2024 guidance and highlighted promising gene therapy data, while addressing ongoing patent litigation and gradual customer adoption of new reimbursement policies.
-
Q2 2024 saw solid sales growth, high gross margins, and strong cash flow, with preparations underway for the NOPAIN Act and expanded GPO partnerships. Patent litigation remains ongoing, but the company is confident in its IP and legal strategy.
-
Q1 results aligned with expectations, with EXPAREL driving growth and new GPO contracts reducing adoption barriers. NOPAIN legislation is set to expand reimbursement opportunities in 2025, while ongoing patent litigation and commercial investments shape the outlook.